Ncardia Adds Six Human Induced Pluripotent Stem Cell-Derived Neuronal Models for CNS Research
The expanded Ncyte portfolio spans dopaminergic, motor, excitatory, GABAergic, sensory and cholinergic neurons, alongside existing glial cell options.

Key Points
- Ncardia added six human induced pluripotent stem cell (iPSC)-derived neuronal models for central nervous system drug discovery, disease modeling and neurotoxicity research.
- The Ncyte portfolio now includes dopaminergic, motor, excitatory, GABAergic, sensory and cholinergic neurons, complementing existing glial cell options.
- The models are intended for in vitro research use only.
Ncardia, a research and development company focused on human iPSC technology, announced six new Ncyte human iPSC-derived neuronal models for central nervous system (CNS) research.
Stay updated on Cell & Gene news
Thanks! Your signup has been saved.
The new models join Ncardia’s existing glial cell options for CNS drug discovery, disease modeling and neurotoxicity research.
Dopaminergic neurons express tyrosine hydroxylase and FOXA2, markers Ncardia uses to characterize the cells. The company positions the model for research into dopamine signaling, Parkinson’s disease mechanisms, and compounds that might protect dopaminergic neurons.
Motor neurons express ISL1/2 and HB9, two markers associated with motor neuron identity. Ncardia lists amyotrophic lateral sclerosis and spinal muscular atrophy as examples of diseases researchers can investigate with the model.
Excitatory neurons are glutamatergic and express vGLUT1, a marker of that identity. The model is designed for studies of how excitatory signals travel across synapses and through neuronal networks, including safety studies that examine seizure risk.
GABAergic neurons model inhibitory signaling and express markers including GAD1 and parvalbumin. Researchers can use them to study the balance between excitation and inhibition, a question relevant to epilepsy and some neurodevelopmental disorders.
Sensory neurons model peripheral sensory cells involved in detecting potentially damaging stimuli. Ncardia identifies chronic and neuropathic pain, peripheral neuropathy, and screening for potential pain medicines as research applications.
Cholinergic neurons express choline acetyltransferase, the enzyme that makes the neurotransmitter acetylcholine. Ncardia describes the cells as a model for studying cholinergic signaling in cognition and memory, including mechanisms relevant to Alzheimer’s disease.
Ncardia says the neuronal models give pharmaceutical and biotechnology researchers access to specialized human cell types without requiring them to establish differentiation workflows in-house. The models are intended for in vitro research use only.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
Similar stories
BrainXell and Neuroservices-Alliance Profile Induced Pluripotent Stem Cell–Derived Sensory Neurons
California Institute for Regenerative Medicine Awards $6.9 Million for Preclinical Development of Stem Cell-Derived Cardiac Muscle Therapy for Severe Heart Attack
CellFiber Opens First International Subsidiary in Philadelphia to Support Cell and Gene Therapy Development
Curi Bio Expands Curiverse 3D Tissue Ecosystem with New Disease Models, Casting Kits, and Assay Services
Matricelf Receives FDA Feedback Supporting Proposed First-in-Human Trial Design for NewRal in Traumatic Spinal Cord Injury
YiPSCELL Receives Korean Patent Registration Decision for Low-Immunogenicity Universal iPSC Technology
SmartCella Licenses Extroducer Endovascular Delivery Platform to HeartWorks for iPSC-Derived Cardiac Cell Therapies
ABEC Launches ATB-2100 Advanced Therapy Bioreactor for Cell and Gene Therapy Manufacturing







